Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Inhibrx (United States) | Researchclopedia

Back to institutions

Inhibrx (United States)

La Jolla, Californiacompany

42

Works

1,784

Citations

28

h-index

Top Research Topics

CAR-T cell therapy research Cancer Immunotherapy and Biomarkers Protease and Inhibitor Mechanisms

Top Researchers

Quinn L. Deveraux Inhibrx (United States)

57 works16,072 citationsh-index: 38

Recent Research

Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial

Francesco Davide Sanvito,Catalina Raymond,et al.

20260 citations

Immunotherapy and Immune Responses

Cell Adhesion Molecules Research

Monoclonal and Polyclonal Antibodies Research

Immune Cell Function and Interaction

Peptidase Inhibition and Analysis

T-cell and B-cell Immunology

Bone Tumor Diagnosis and Treatments

Cell death mechanisms and regulation

Inflammatory mediators and NSAID effects

Elgene Lim New South Wales Department of Health

358 works15,866 citationsh-index: 53

Igor Barjaktarević University of California, Los Angeles

410 works9,532 citationsh-index: 37

Zbigniew Nowecki Maria Curie-Skłodowska University

221 works9,389 citationsh-index: 41

Shahram Salek‐Ardakani Inhibrx (United States)

92 works5,476 citationsh-index: 41

Yung‐Chang Lin Ningbo University

202 works4,233 citationsh-index: 33

Editorial: Follicular helper T cells in immunity and autoimmunity, volume II

Shahram Salek‐Ardakani,Georgia Fousteri,et al.

20260 citations

THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY

Robin L. Jones,Victoria Wang,et al.

20251 citations

EXTH-100. Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ

Katelyn M. Willis,William Crago,et al.

20250 citations

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Jong Chul Park,Lisa Licitra,et al.

20250 citations

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Nisha Holay,Rashi Yadav,et al.

20259 citations